Clinical effect of early administration of tocilizumab following the initiation of corticosteroid therapy for patients with COVID-19.

ABSTRACT:

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in Wuhan in December 2019, and has since caused a global pandemic. The efficacy of several drugs has been evaluated, and it is now evident that tocilizumab has a beneficial effect, especially combined with corticosteroids, in patients with Coronavirus Disease 2019 (COVID-19). However, the optimal timing of tocilizumab administration has not yet been established. The goal of the present study was to determine the optimal timing of tocilizumab administration after starting corticosteroid therapy in patients with COVID-19.

Methods

We retrospectively analyzed the clinical characteristics of patients who were hospitalized for COVID-19 and treated with tocilizumab and corticosteroids in our h

SUBMITTER: Kawamata T 

PROVIDER: S-EPMC9428329 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature